Therapeutic Management and Long-Term Outcome of Hyperthyroidism in Patients with Antithyroid-Induced Agranulocytosis: A Retrospective, Multicenter Study
Carlos García Gómez(Hospital Universitario Puerta de Hierro Majadahonda), Pedro Iglesias(Hospital Universitario Puerta de Hierro Majadahonda), Carles Villabona(Bellvitge University Hospital), Francisco Arrieta(Hospital Universitario Ramón y Cajal), Emma Anda(Complejo Hospitalario de Navarra), Fernando Guerrero‐Pérez(Bellvitge University Hospital), Andrés Ruiz de Assín Valverde(Complejo Hospitalario Universitario de Albacete), Cristina Lamas(Hospital General Universitario de Albacete), Victoria Alcázar(Hospital Universitario Severo Ochoa), Juan J. Díez(Instituto Cajal), José Antonio Rosado Sierra(Hospital Universitario de Getafe), Betina Biagetti(Vall d'Hebron Institut de Recerca), Julia Sastre(Complejo Hospitalario Universitario de Toledo), Beatriz Lecumberri(Hospital Universitario La Paz), Antonio López-Guzmán(Catholic University of Ávila), Elena Navarro(Hospital Universitario Virgen del Rocío)
Cited by 4
Related Papers
Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement
|Nature Reviews Endocrinology|2018|346
Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients
|Endocrine Related Cancer|2015|204
From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network
|European Journal of Endocrinology|2016|174
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
|Annals of Oncology|2015|157
GLUT1 deficiency and other glucose transporter diseases
|European Journal of Endocrinology|2004|145